Natural antisense transcripts as drug targets
The recent discovery of vast non-coding RNA-based regulatory networks that can be easily modulated by nucleic acid-based drugs has opened numerous new therapeutic possibilities. Long non-coding RNA, and natural antisense transcripts (NATs) in particular, play a significant role in networks that invo...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-09-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2022.978375/full |
| _version_ | 1811255070472273920 |
|---|---|
| author | Olga Khorkova Jack Stahl Aswathy Joji Aswathy Joji Claude-Henry Volmar Zane Zeier Claes Wahlestedt Claes Wahlestedt |
| author_facet | Olga Khorkova Jack Stahl Aswathy Joji Aswathy Joji Claude-Henry Volmar Zane Zeier Claes Wahlestedt Claes Wahlestedt |
| author_sort | Olga Khorkova |
| collection | DOAJ |
| description | The recent discovery of vast non-coding RNA-based regulatory networks that can be easily modulated by nucleic acid-based drugs has opened numerous new therapeutic possibilities. Long non-coding RNA, and natural antisense transcripts (NATs) in particular, play a significant role in networks that involve a wide variety of disease-relevant biological mechanisms such as transcription, splicing, translation, mRNA degradation and others. Currently, significant efforts are dedicated to harnessing these newly emerging NAT-mediated biological mechanisms for therapeutic purposes. This review will highlight the recent clinical and pre-clinical developments in this field and survey the advances in nucleic acid-based drug technologies that make these developments possible. |
| first_indexed | 2024-04-12T17:18:14Z |
| format | Article |
| id | doaj.art-d4ca65355a0748f08b6c9e3f7439f124 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-04-12T17:18:14Z |
| publishDate | 2022-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-d4ca65355a0748f08b6c9e3f7439f1242022-12-22T03:23:35ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2022-09-01910.3389/fmolb.2022.978375978375Natural antisense transcripts as drug targetsOlga Khorkova0Jack Stahl1Aswathy Joji2Aswathy Joji3Claude-Henry Volmar4Zane Zeier5Claes Wahlestedt6Claes Wahlestedt7Center for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United StatesCenter for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United StatesCenter for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United StatesDepartment of Chemistry, University of Miami, Miami, FL, United StatesCenter for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United StatesCenter for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United StatesCenter for Therapeutic Innovation and Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United StatesDepartment of Chemistry, University of Miami, Miami, FL, United StatesThe recent discovery of vast non-coding RNA-based regulatory networks that can be easily modulated by nucleic acid-based drugs has opened numerous new therapeutic possibilities. Long non-coding RNA, and natural antisense transcripts (NATs) in particular, play a significant role in networks that involve a wide variety of disease-relevant biological mechanisms such as transcription, splicing, translation, mRNA degradation and others. Currently, significant efforts are dedicated to harnessing these newly emerging NAT-mediated biological mechanisms for therapeutic purposes. This review will highlight the recent clinical and pre-clinical developments in this field and survey the advances in nucleic acid-based drug technologies that make these developments possible.https://www.frontiersin.org/articles/10.3389/fmolb.2022.978375/fullnatural antisense transcript (NAT)long nocoding RNAanisense oligonucleotidesposttranscriptional regulationnucleic acid based therapeutics |
| spellingShingle | Olga Khorkova Jack Stahl Aswathy Joji Aswathy Joji Claude-Henry Volmar Zane Zeier Claes Wahlestedt Claes Wahlestedt Natural antisense transcripts as drug targets Frontiers in Molecular Biosciences natural antisense transcript (NAT) long nocoding RNA anisense oligonucleotides posttranscriptional regulation nucleic acid based therapeutics |
| title | Natural antisense transcripts as drug targets |
| title_full | Natural antisense transcripts as drug targets |
| title_fullStr | Natural antisense transcripts as drug targets |
| title_full_unstemmed | Natural antisense transcripts as drug targets |
| title_short | Natural antisense transcripts as drug targets |
| title_sort | natural antisense transcripts as drug targets |
| topic | natural antisense transcript (NAT) long nocoding RNA anisense oligonucleotides posttranscriptional regulation nucleic acid based therapeutics |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2022.978375/full |
| work_keys_str_mv | AT olgakhorkova naturalantisensetranscriptsasdrugtargets AT jackstahl naturalantisensetranscriptsasdrugtargets AT aswathyjoji naturalantisensetranscriptsasdrugtargets AT aswathyjoji naturalantisensetranscriptsasdrugtargets AT claudehenryvolmar naturalantisensetranscriptsasdrugtargets AT zanezeier naturalantisensetranscriptsasdrugtargets AT claeswahlestedt naturalantisensetranscriptsasdrugtargets AT claeswahlestedt naturalantisensetranscriptsasdrugtargets |